Trial
NCT02036502
A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Multiple Myeloma
Intervention
Pembrolizumab
Why stopped
Business Reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-04-08